Top-line data now expected to be announced in Q1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
… ProQR Announces a Proof-of-Concept Nasal Potential Difference … the Netherlands, Sept. 14, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … said Noreen R. Henig, MD, Chief Development Officer of ProQR. "This study is an important proof-of-concept study …